Skip to main content
Premium Trial:

Request an Annual Quote

Synchron Buys French Biomarker, Dx Services Lab for $6.7M

NEW YORK (GenomeWeb News) - Indian clinical research organization Synchron Research Services has acquired from Parexel a biomarker and bioanalytical research facility based in France for around $6.7 million, Synchron said today.
 
The lab, which is located in Poitiers, France, and was bought by Parexel in 1999, will now be called Synexel Research International. The lab offers singleplexed and multiplexed immunoassay platforms that support early clinical, pre-clinical, and clinical studies, as well as biomarker research programs.
 
Synchron said the lab is GLP Class A certified by Afssaps, France.
 
Ahmedabad-based Synchron said it has agreed to retain all of the staff and management team at the Synexel facility.
 
In addition to the acquisition, Synchron said that Parexel had increased the stake it owns in Synchron from 19.5 percent to 31 percent, but it did not disclose the amount of the investment.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.